Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasChimeric Antigen Receptors Modified T-Cells for Cancer TherapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsCAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in LymphomaImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsSmart CARs engineered for cancer immunotherapyFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceBispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Novel Immunotherapies for Multiple Myeloma.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.Adoptive therapy with CAR redirected T cells for hematological malignancies.Recent advances in T-cell immunotherapy for haematological malignancies.Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.Development of CAR T cells designed to improve antitumor efficacy and safety.Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the FuelChimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.Overcoming Antigen Escape with CAR T-cell Therapy.Practical considerations for chimeric antigen receptor design and delivery.Prospects for combined use of oncolytic viruses and CAR T-cells.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.CAR T cell therapy for multiple myeloma: where are we now and where are we headed?Chimeric antigen receptor transduced T cells: Tuning up for the next generation.New Chimeric Antigen Receptor Design for Solid Tumors.Mechanisms regulating T-cell infiltration and activity in solid tumors.T-bet promotes potent antitumor activity of CD4+ CAR T cells.Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
P2860
Q26745600-D4195D71-4C37-4A59-A795-FA19D9BBE44AQ26749139-FB926AAC-F6DD-4B44-8EB3-E69ABB52EB73Q26773309-9E9C1746-584F-49FE-BC8E-5B1D409B1985Q26778759-79C7015C-99BE-4A59-A5B0-42DD32C7B940Q26800814-F75A3974-0FB3-4357-8FC4-75B11F663C45Q28068378-A10FC021-2497-43AA-8CAA-CBB85D5CDAF7Q28079823-E378B355-EB16-4541-AAC2-C1D3EBBA1912Q28087236-4E1A1A31-F7B2-46E3-9D96-021DD1F0D5AFQ33607015-B32BC610-D822-4804-B396-185ECFE18ADEQ34517676-532C27AD-5F83-4448-AC34-769AF3CEDCB4Q37609801-5E6AACAD-988B-4A68-A3F0-53DEE3DDE2CEQ37728639-903387BF-B109-4D1D-8BB7-A70D020992BEQ38640444-D535D851-4C11-4B4E-9B50-B95189229DF6Q38764944-3E00C87F-67EF-472A-96A4-BCAB1E48AD4EQ38770555-036506D9-5F48-4889-91E2-2346E729A8B3Q38775177-A06E83FC-35C4-442D-B229-43703F9006BAQ38779032-FB731CF6-CE7B-480A-89DB-B5F288884220Q38786628-A19F73EA-329B-4C87-AC22-EBA7F1F14783Q38789518-98FCCBE8-51F1-4654-9DF6-61E2656E8BDEQ38890450-8F2725C0-6714-4D92-95A0-7B83CB345128Q38945853-07D90640-6573-4816-93AF-2AC94EA41A29Q39039017-216347F7-0F6A-4B86-BA2D-3B447789F95DQ39194733-8321EB27-D5DE-4B56-8F91-59A014406ECBQ39200527-F2C171FD-5E03-489D-8C60-24C0F1C1227BQ39249589-12830E96-26EB-4C89-9499-EB6433D592A8Q39401736-84F1711D-6FCB-4825-BFBC-071A79CEF862Q39798588-9DC1FC91-BE01-4AC5-B264-E8CB31A1F757Q41183738-A74D40BA-7BD5-464A-B18E-F6BBB7438F37Q45868559-84D9F27B-2A27-41B2-9E40-5CFE98FB6911Q47103891-43D93F5E-AE0A-44BA-9B3D-218905E61343Q47193084-0B5B8049-EA79-4513-B7F1-348510E840DBQ47565827-FA053442-FBBF-4875-A3A0-22EE5FDC9B1BQ48337005-EFCC13CB-CB32-4711-9B91-C92CA430482BQ49711158-4B636A9D-FB06-4188-A616-BD27264AA3EEQ50089395-9191E8B8-ED86-4B08-A09C-C97E7F3C5BFEQ52668512-F36628B6-F203-4207-9675-033D3AE56229Q54965277-BF73D408-6339-4496-99B4-76B3A16132AE
P2860
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@ast
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@en
type
label
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@ast
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@en
prefLabel
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@ast
Enhancing antitumor efficacy o ...... constitutive CD40L expression.
@en
P2093
P2860
P356
P1433
P1476
Enhancing antitumor efficacy o ...... constitutive CD40L expression
@en
P2093
Beatrijs A Seinstra
Dayenne G van Leeuwen
Hollie J Pegram
Kevin J Curran
Raymond Yeh
Renier J Brentjens
Yan Nikhamin
Yelena Usachenko
P2860
P304
P356
10.1038/MT.2015.4
P577
2015-01-13T00:00:00Z